Study of the Immune Cell Response After Hepatitis B Vaccination in Adults

What this Trial Is About

Researchers are studying the immune response in healthy adults who receive the hepatitis B virus HBV vaccine. This observational study focuses on understanding how certain immune cells called T lymphocytes respond after vaccination, especially those targeting the HBV surface antigen. The goal is to better understand the biological mechanisms behind vaccine-induced protection against hepatitis B, a virus that affects millions worldwide and can cause serious liver disease despite existing vaccines and treatments. Participants will undergo evaluation of their cellular immune response through advanced techniques like spectral cytometry to detect specific T lymphocytes after receiving the HBV vaccine. The study will measure the frequency and functional characteristics of these immune cells and correlate them with antibody levels against HBV. The study involves healthy individuals receiving vaccination without any experimental drug or placebo. During the study, participants will provide blood samples for immune cell analysis and antibody testing before vaccination. Researchers will measure the proportion of individuals with a cellular immune response, levels of anti-HBsAg antibodies, and percentages of certain T lymphocyte types. Participants health and immune status will be monitored, and the study aims to collect detailed cellular and molecular data to understand long-term vaccine protection. The study participation period is not specifically detailed but includes evaluations at inclusion.

Study of the Cellular Response Induced After Vaccination Against the Hepatitis B Virus